Companies: 10,795·Total market cap: $144.5T
CytoMed Therapeutics Limited

CytoMed Therapeutics Limited

GDTCNASDAQHealthcare● Active
$1.15
$-0.14(-10.85%)
Market Cap$13607760
P/E Ratio—
52W High$3.68
52W Low$0.68
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

CytoMed Therapeutics Limited (GDTC) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · GDTC · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-0.46gdtc eps ttm · gdtc earnings per shareEarnings history
PE Ratio (TTM)—gdtc pe ratio ttm · gdtc price to earningsPE Ratio deep dive
Revenue (TTM)509129.00gdtc revenue ttm · gdtc annual revenueFull revenue history
Dividend YieldNo Dividenddoes gdtc pay dividends · gdtc dividend yieldDividend history
Shares Outstanding11.6Mgdtc shares outstanding · gdtc floatShares outstanding history
Next EarningsNov 13, 2026Est.gdtc earnings date · gdtc next earningsEarnings history

Explore CytoMed Therapeutics Limited Data

gdtc stock data · financials
Market Cap$13.6Mgdtc market cap · gdtc valuation
Analyst Forecast$— · Buy
DividendsNo Dividenddoes cytomed therapeutics limited pay dividends · gdtc dividend yield
Revenue$319201+359.28%cytomed therapeutics limited annual revenue · gdtc revenue
EarningsEPS $-0.33-50.00%gdtc earnings · gdtc eps
PE Ratio—gdtc pe ratio · gdtc price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$319201.00▲ +359.28% YoY
202320242025
cytomed therapeutics limited revenue · gdtc revenue 2025
FY 2025Net Income-$3.9M▼ 52.33% YoY
202320242025
cytomed therapeutics limited net income · gdtc profit 2025
FY 2025EPS$-0.33▼ 50.00% YoY
202320242025
gdtc eps · cytomed therapeutics limited earnings per share 2025
TTM:Revenue: $509129.00Net Income: -$5.5MEPS: $-0.46View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy1 analystsis gdtc a buy · gdtc analyst rating
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$—Low
$1.15Current
$—Avg Target
$—High
gdtc price target · gdtc 12 month forecast

Total: 1 · Buy rate: 100.0%

Stock Performance

Full History
1D-10.85%
1W+2.68%
1M+47.44%
3M+9.52%
YTD-14.18%
1Y-44.98%
5Y-71.25%

About CytoMed Therapeutics Limited

CEOChee Kong Choo
IPO DateApr 14, 2023
Employees43
CountrySG
Websitew2.cytomed.sg

CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunother…

BiotechnologyHealthcareNASDAQSG

what is cytomed therapeutics limited · gdtc stock overview · cytomed therapeutics limited company profile · who is cytomed therapeutics limited ceo · gdtc NASDAQ · cytomed therapeutics limited headquarters · cytomed therapeutics limited business segments

About Stock Overview & Key Data

CytoMed Therapeutics Limited (GDTC) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 14, 2023. As of the latest trading session, GDTC stock price is $1.15, with a market capitalization of $13.6M. The stock has returned -44.98% over the past 12 months and -14.18% year-to-date.

According to 1 Wall Street analysts, the consensus rating for CytoMed Therapeutics Limited stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, CytoMed Therapeutics Limited reported revenue of $319201.00 and net income of -$3.9M. For detailed data — including CytoMed Therapeutics Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, CytoMed Therapeutics Limited (GDTC) stock price is $1.15. The stock is traded on NASDAQ under the ticker symbol GDTC. The 52-week range is $0.68 – $3.68.

GDTC stock priceGDTC quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice